A group of researchers coordinated by the Institute of Myology has focused on a small contingent of cells and their potential use in the treatment of myasthenia gravis (MG):
- these stromal cells derive from the mesenchyme and play a role in regulating immunomodulation when they are brought into contact with mononuclear blood cells,
- several functional approaches ranging from RNA-Seq to mass and flow cytometry, including secretome analysis, were used.
- studies of this cell population were carried out in a basal state, in the presence of the mononuclear cells in question, or following stimulation by interferon gamma, all in vitro and in MG animal models.
- The different transcriptomic profiles obtained confirm the beneficial nature of this cell contingent.
Although very fundamental, this work could ultimately lead to new therapeutic avenues in MG.
